Seagen announces adcetris® (brentuximab vedotin) plus novel immunotherapy combination delivers 98% overall response rate and 93% complete response rate in patients with early-stage classical hodgkin lymphoma (chl)

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced updated efficacy and safety results from part c of a phase 2 single-arm trial (sgn35-027) evaluating the antibody-drug conjugate adcetris® (brentuximab vedotin) in combination with the pd-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (an+ad) for the frontline treatment of patients with early-stage classical hodgkin lymphoma (chl). data results will be presented at the 17th internatio.
SGEN Ratings Summary
SGEN Quant Ranking